- Fellowship - Cleveland Clinic Foundation (2016-2019), Hematology Oncology
- Residency - Cleveland Clinic Foundation (2013-2016), Internal Medicine
- Residency - King Hussein Cancer Center, Jordan (2012-2013), Internal Medicine
- Internship - Al-Hussein Hospital, Jordan (2011-2012), General Medicine & Surgery
- Medical School - University of Jordan Faculty of Medicine, Jordan (2005-2011)
Yazan Madanat, M.D.
- Internal Medicine - Hematology/Oncology
Yazan Madanat, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center.
Dr. Madanat earned his medical degree at the University of Jordan. He completed his residency training in internal medicine at the Cleveland Clinic and then received advanced training in hematology and medical oncology through a fellowship at the Cleveland Clinic Taussig Cancer Institute.
Certified by the American Board of Internal Medicine, he joined the UT Southwestern leukemia and hematopoietic cell transplant program in the Division of Hematology and Oncology in 2019.
Dr. Madanat is a member of several professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physicians. He earned Abstract Achievement Awards from the American Society of Hematology for two consecutive years (2017 and 2018) and received an honorable distinction award from the Society of Hematologic Oncology in 2018.
He has delivered several presentations and published numerous academic articles and book chapters that focus on the treatment of myeloid malignancies, acute leukemia, and myelodysplastic syndromes.
Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?
Madanat YF, Gerds AT, Best practice & research. Clinical haematology 2019 03 32 1 104-113
Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT, Clinical lymphoma, myeloma & leukemia 2017 Dec 17 12 857-862
Wilms tumor 1 expression: addressing the 'elephant' in MDS.
Madanat YF, Sekeres MA, Leukemia & lymphoma 2019 Mar 60 3 566-567
Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
Madanat Y, Sekeres MA, Seminars in hematology 2017 07 54 3 147-153
Got zinc? An exfoliative rash in a parenteral nutrition-dependent patient.
Sidana S, Madanat Y, Pile J, Journal of general internal medicine 2015 Apr 30 4 529-30
Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?
Madanat YF, Kalaycio ME, Nazha A, Acta medica academica 2019 Apr 48 1 35-44
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas.
Madanat YF, Smith MR, Almasan A, Hill BT, Blood and lymphatic cancer : targets and therapy 2016 6 1-6
- Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?
Showing 1 locations